HOLEKAMP, TERRENCE FLETCHER,KELLY, MICHAEL PATRICK,LENKE, LAWRENCE GERARD
申请号：
CA3053122
公开号：
CA3053122A1
申请日:
2018.02.08
申请国别(地区):
CA
年份:
2018
代理人:
摘要：
A new method of targeted intrasite drug administration to wounds offers advantages in treatment efficacy and safety over traditional routes of administration. A novel method of dosing intrasite medications based on wound surface area provides the parameters for safe and effective dosing, a necessary advance for any FDA approval. Large intrasite doses increase risk of toxicity from impurities allowed in drugs given by other routes. Pharmacodynamic parameters make certain drugs advantageous as intrasite agents, including slow trans-wound surface diffusion, protein binding, and limited local tissue toxicity. Vancomycin is a prototypical drug with these features and is therefore very useful as an intrasite medication. Other drugs, including but not limited to rifaximin, possess similar pharmacodynamics and may be useful intrasite pharmaceuticals, delivered alone or in combination with other drugs, carriers, or materials. All of these attributes are advantages over traditional administration methods.
